Table 1 PSL-IV individual item change scores post CO2 challenge.

From: Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans

 

Placebo

JNJ-61393215 25 mg of QD

Placebo

JNJ-61393215 90 mg of QD

Placebo

Alprazolam 1 mg of BID

Dizziness

1.9 (1.08)

1.3 (1.22)

2.3 (1.06)

1.8 (1.09)

2.1 (0.92)

1.7 (1.19)

Choking/gasping for breath

1.8 (0.83)

1.9 (0.90)

2.5 (1.38)

1.8 (1.28)

2.1 (0.92)

1.9 (1.30)

Hot flashes/cold shivers

0.3 (0.75)

0.3 (0.65)

0.9 (1.56)

0.5 (1.33)

0.8 (1.25)

0.2 (0.40)

Nausea

0.4 (0.51)

0.2 (0.39)

0.7 (1.23)

0.5 (1.33)

0.3 (0.61)

0.1 (0.30)

Palpitations

1.9 (1.08)

1.3 (1.15)

1.8 (1.27)

1.8 (1.28)

1.9 (0.95)

1.3 (0.90)

Sweating

0.7 (0.49)

0.8 (0.94)

1.3 (1.29)

0.9 (0.86)

1.3 (1.14)

1.0 (0.89)

Shortness of breath

1.6 (1.00)

1.8 (0.97)

2.3 (1.15)

2.1 (1.32)

2.2 (0.89)

1.9 (1.22)

Numb/tingling

0.8 (0.94)

0.7 (1.07)

1.5 (1.0)

1.2 (1.36)

0.9 (0.95)

0.7 (0.79)

Depersonalization/derealization

0.5 (0.80)

0.6 (0.79)

1.2 (1.47)

1.2 (1.41)

1.1 (1.10)

0.8 (0.98)

Fear of dying

0.1 (0.29)

0.1 (0.29)

0.3 (0.89)

0.4 (1.12)

0.3 (0.73)

0.1 (0.30)

Fear of losing control

0.3 (0.65)

0.3 (0.65)

0.4 (0.90)

0.4 (0.87)

0.3 (0.61)

0.4 (0.50)

Chest pain discomfort

0.3 (0.45)

0.2 (0.39)

0.8 (1.14)

0.7 (1.18)

0.1 (0.36)

0 (0)

Trembling/shaking

1.3 (0.87)

1.3 (0.97)

1.6 (1.51)

1.4 (1.39)

1.1 (1.27)

1.2 (1.54)

  1. BID twice daily, PSL-IV panic symptom list IV, SD standard deviation, QD once daily.
  2. Data are represented as mean (SD).